Results for visual function questionnaire translation from Danish to English

i en kombineret dataanalyse af galileo og copernicus viste eylea klinisk relevante ændringer fra baseline i det forudspecificerede sekundære virkningsendepunkt national eye institute visual function questionnaire (nei vfq-25).
in combined data analysis of galileo and copernicus, eylea demonstrated clinically meaningful changes from baseline in pre-specified secondary efficacy endpoint national eye institute visual function questionnaire (nei vfq-25).

i en kombineret dataanalyse af galileo og copernicus viste eylea klinisk relevante ændringer fra baseline i det forudspecificerede sekundære virkningsendepunkt i national eye institute visual function questionnaire (nei vfq-25).
in combined data analysis of galileo and copernicus, eylea demonstrated clinically meaningful changes from baseline in pre-specified secondary efficacy endpoint national eye institute visual function questionnaire (nei vfq-25).

i den integrerede analyse fra national eye institute visual function questionnaire 25 (vfq 25) viste hver subskala-score og den sammensatte score også en numerisk forbedring til fordel for jetrea over for placebo.
in the integrated analysis of the national eye institute visual function questionnaire-25 (vfq-25), a numerical favour of jetrea over placebo was shown in each sub-scale score, as well as the composite score.

i den kombinerede dataanalyse af view1 og view2 viste eylea klinisk betydningsfulde ændringer fra baseline i spørgeskemaet national eye institute visual function questionnaire (nei vfq-25) uden klinisk betydningsfulde forskelle i forhold til ranibizumab.
in combined data analysis of view1 and view2 eylea demonstrated clinically meaningful changes from baseline in pre-specified secondary efficacy endpoint national eye institute visual function questionnaire (nei vfq-25) without clinically meaningful differences to ranibizumab.

statistisk signifikante patientrapporterede fordele med hensyn til synsfunktion blev observeret i både marina og anchor ved behandling med ranibizumab i forhold til kontrolgruppen, bedømt ved nei vfq-25 (national eye institute visual function questionnaire).
statistically significant patient-reported visual functioning benefits were observed in both marina and anchor with ranibizumab treatment over the control group as measured by the nei vfq-25.

i både marina og anchor studierne, blev de forbedringer, der blev set i synsstyrken med lucentis 0, 5 mg ved 12 måneder, overført til patient-rapporterede fordele.disse fordele blev målt på de tre delskalaer af national eye institue visual function questionnaire (vfq-25) , som var forud bestemt som sekundære endepunkter (læsesyn, afstandssyn, og synsspecifik afhængighed) .
in both the marina and anchor studies, the improvement in visual acuity seen with lucentis 0.5 mg at 12 months translated into patient-reported benefits as measured on the three subscales of the national eye institute visual function questionnaire (vfq-25) which were pre-specified secondary efficacy endpoints (near activities, distance activities, and vision-specific dependency) .